Metastatic Urothelial Cancer
Oncology
4
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
ADC
1100%
+ 3 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
GS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Gilead SciencesSacituzumab Govitecan-hziy
TakedaPaclitaxel and TAK-228
PfizerAGS15E
Clinical Trials (3)
Total enrollment: 972 patients across 3 trials
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Start: Aug 2018Est. completion: Apr 2030827 patients
Phase 2Recruiting
Paclitaxel and TAK-228 in Urothelial Carcinoma
Start: May 2018Est. completion: Nov 202052 patients
Phase 2Unknown
ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Start: Nov 2013Est. completion: Jul 201993 patients
Phase 1Completed
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
16m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
16m ago
Office Administrator
SystImmune
16m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
27m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
30m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
30m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 972 patients
4 companies competing in this space